FAQ: What Is the Efficacy of Switching MOA to Guselkumab After Inadequate Response to a single TNFi?
Автор: RhAPP Digital
Загружено: 2026-03-09
Просмотров: 3
Описание: In this FAQ video, Will Saalfeld, NP, reviews the clinical efficacy of switching to guselkumab after an inadequate response to a TNF inhibitor in psoriatic arthritis. The discussion highlights key trial data from DISCOVER-1 and COSMOS, real-world outcomes, and improvements in joint and skin disease, including ACR20 response rates, low disease activity, and remission through one year. Safety, durability, and the rationale for IL-23 pathway targeting are also reviewed to support evidence-based treatment decisions in TNF-experienced patients. For more educational content, visit the RhAPP Content Rheum or RhAPP ACE app.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
